Moleculin Biotech, Inc.

NasdaqCM:MBRX Voorraadrapport

Marktkapitalisatie: US$7.0m

Moleculin Biotech Beheer

Beheer criteriumcontroles 3/4

De CEO Moleculin Biotech is Wally Klemp, benoemd in Jul2015, heeft een ambtstermijn van 9.33 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.41M, bestaande uit 39.9% salaris en 60.1% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 2.56% van de aandelen van het bedrijf, ter waarde $ 178.69K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 7.1 jaar en 7.3 jaar.

Belangrijke informatie

Wally Klemp

Algemeen directeur

US$1.4m

Totale compensatie

Percentage CEO-salaris39.9%
Dienstverband CEO9.3yrs
Eigendom CEO2.6%
Management gemiddelde ambtstermijn7.1yrs
Gemiddelde ambtstermijn bestuur7.3yrs

Recente managementupdates

Recent updates

We're A Little Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Rate

Dec 20
We're A Little Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Rate

Can Moleculin Biotech (NASDAQ:MBRX) Afford To Invest In Growth?

Jul 14
Can Moleculin Biotech (NASDAQ:MBRX) Afford To Invest In Growth?

Is Moleculin Biotech (NASDAQ:MBRX) In A Good Position To Deliver On Growth Plans?

Feb 18
Is Moleculin Biotech (NASDAQ:MBRX) In A Good Position To Deliver On Growth Plans?

Here's Why We're Watching Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation

Nov 01
Here's Why We're Watching Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation

Moleculin Biotech rises 7% as WP1096 compound selected for NIAID-funded animal studies

Sep 27

Moleculin brain cancer therapy WP1122 gets FDA orphan drug status

Sep 06

Here's Why We're Not Too Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation

Jul 11
Here's Why We're Not Too Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation

Moleculin potential COVID drug WP1122 shows safety in preliminary data from phase 1a trial

Jul 08

We Think Moleculin Biotech (NASDAQ:MBRX) Can Afford To Drive Business Growth

Mar 28
We Think Moleculin Biotech (NASDAQ:MBRX) Can Afford To Drive Business Growth

We're Not Very Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Rate

Dec 11
We're Not Very Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Rate

We Think Moleculin Biotech (NASDAQ:MBRX) Can Afford To Drive Business Growth

Aug 18
We Think Moleculin Biotech (NASDAQ:MBRX) Can Afford To Drive Business Growth

Moleculin Biotech to join Russell 2000 Index

Jun 15

Is Moleculin Biotech (NASDAQ:MBRX) In A Good Position To Invest In Growth?

May 04
Is Moleculin Biotech (NASDAQ:MBRX) In A Good Position To Invest In Growth?

Moleculin shares soar after promising Annamycin pre-clinical readout

Feb 02

Moleculin Biotech under pressure on reverse stock split

Jan 29

Here's Why We're A Bit Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation

Jan 15
Here's Why We're A Bit Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation

Moleculin Bio's Annamycin an Orphan Drug in U.S. for soft tissue sarcomas

Dec 29

Analyse CEO-vergoeding

Hoe is Wally Klemp's beloning veranderd ten opzichte van Moleculin Biotech's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

-US$25m

Mar 31 2024n/an/a

-US$27m

Dec 31 2023US$1mUS$565k

-US$30m

Sep 30 2023n/an/a

-US$26m

Jun 30 2023n/an/a

-US$29m

Mar 31 2023n/an/a

-US$30m

Dec 31 2022US$2mUS$565k

-US$29m

Sep 30 2022n/an/a

-US$25m

Jun 30 2022n/an/a

-US$21m

Mar 31 2022n/an/a

-US$18m

Dec 31 2021US$2mUS$538k

-US$16m

Sep 30 2021n/an/a

-US$16m

Jun 30 2021n/an/a

-US$15m

Mar 31 2021n/an/a

-US$21m

Dec 31 2020US$2mUS$500k

-US$17m

Sep 30 2020n/an/a

-US$19m

Jun 30 2020n/an/a

-US$19m

Mar 31 2020n/an/a

-US$10m

Dec 31 2019US$2mUS$625k

-US$13m

Sep 30 2019n/an/a

-US$12m

Jun 30 2019n/an/a

-US$10m

Mar 31 2019n/an/a

-US$14m

Dec 31 2018US$1mUS$403k

-US$12m

Sep 30 2018n/an/a

-US$12m

Jun 30 2018n/an/a

-US$13m

Mar 31 2018n/an/a

-US$11m

Dec 31 2017US$1mUS$325k

-US$10m

Compensatie versus markt: De totale vergoeding ($USD 1.41M ) Wally } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 655.65K ).

Compensatie versus inkomsten: De vergoeding van Wally is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.


CEO

Wally Klemp (64 yo)

9.3yrs

Tenure

US$1,414,599

Compensatie

Mr. Walter V. Klemp, also known as Wally, has been the Executive Chairman of Autonomix Medical, Inc. since joining in January 2022. He Co-Founded Moleculin Biotech, Inc. in July 2015 and has been its Chief...


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Walter Klemp
Co-Founder9.3yrsUS$1.41m2.56%
$ 178.7k
Jonathan Foster
Executive VP & CFO8.3yrsUS$840.64k0.40%
$ 27.8k
Donald Picker
Chief Scientific Officer7.3yrsUS$599.11k0.28%
$ 19.6k
Waldemar Priebe
Co-Founderno datageen gegevensgeen gegevens
John Waymack
Senior Chief Medical Officer3.1yrsgeen gegevensgeen gegevens
Sandra Silberman
Chief Medical Officer of New Products7yrsgeen gegevensgeen gegevens
Wolfram C. Dempke
European Chief Medical Officer2.5yrsgeen gegevensgeen gegevens

7.1yrs

Gemiddelde duur

69yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van MBRX is doorgewinterd en ervaren (gemiddelde ambtstermijn van 7.1 jaar).


Bestuursleden

NaamPositieTenureCompensatieEigendom
Walter Klemp
Co-Founder9.3yrsUS$1.41m2.56%
$ 178.7k
Waldemar Priebe
Co-Founderno datageen gegevensgeen gegevens
Michael Cannon
Independent Director8.4yrsUS$68.52k0%
$ 0
John Climaco
Lead Independent Director7.3yrsUS$81.05k0%
$ 0
Elizabeth Cermak
Independent Director4.1yrsUS$63.52k0%
$ 0
Martin Tallman
Member of Annamycin Scientific Advisory Boardless than a yeargeen gegevensgeen gegevens
Robert George
Independent Director8.4yrsUS$74.90k0.034%
$ 2.4k
Joy Yan
Independent Director2.7yrsUS$47.15k0%
$ 0

7.3yrs

Gemiddelde duur

65yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van MBRX wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.3 jaar).